Nelfinavir, an HIV-1 protease inhibitor, is an essential salvage therapy for treating non-mutational drug tolerance developed in BRAF- and NRAS-mutant melanomas during the therapy phase due to a PAX-3-mediated increased expression of the MITF gene [96]. This evidence concerns the gene NRAS and melanoma.